



Received on 23 January, 2016; received in revised form, 23 February, 2016; accepted, 17 March, 2016; published 01 June, 2016

## A CASE CONTROL STUDY OF ANTIOXIDANT AND OXIDANT STATUS IN TUNISIAN RHEUMATOID ARTHRITIS PATIENTS

M. Ben-Hadj Mohamed <sup>\*1</sup>, S. Khelil <sup>1</sup>, M. Ben Dbibis <sup>1</sup>, L. Khlifi <sup>1</sup>, H. Chahed <sup>1</sup>, S. Ferchichi <sup>1</sup>, E. Bouajina <sup>2</sup> and A. Miled <sup>1</sup>

Biochemistry laboratory <sup>1</sup>, Rheumatology department <sup>2</sup>, Farhat Hached hospital, Sousse, Tunisia.

### Key words:

Antioxidant enzyme,  
Homocysteine, Malondialdehyde,  
Pro-oxidants, Rheumatoid arthritis,  
Total Antioxidant Status.

### Correspondence to Author:

**Ben-Hadj-Mohamed Manel**

Ph.D researcher  
Biochemistry Laboratory, Farhat  
Hached Hospital, Dr Moreau street,  
4000, Sousse, Tunisia.

**E-mail:** manelbhm@gmail.com

**ABSTRACT:** Rheumatoid arthritis is a chronic inflammatory disease with several triggers such as oxidative stress. The aim of this study was to assess the antioxidant enzyme activities (superoxide dismutase, glutathione peroxidase, glutathione reductase and catalase), the total antioxidant status, lipid peroxidation (malondialdehyde) and homocysteine levels in patients with rheumatoid arthritis. The study population consists of 172 patients with rheumatoid arthritis and 147 healthy controls. The glutathione peroxidase and the glutathione reductase erythrocyte activities were determined at 340 nm. The catalase activity was measured by colorimetric assay (Góth). The superoxide dismutase activity and the total antioxidant status levels were calculated using the colorimetric method at 505 nm and 600 nm respectively. Plasma malondialdehyde was determined by the spectrofluorometric method of Yagi. Serum homocysteine was measured by fluorescence polarization immunoassay. Glutathione peroxidase, glutathione reductase and catalase activities and total antioxidant status levels were significantly lower in patients compared to controls. However, malondialdehyde and homocysteine levels in patients were significantly higher than in healthy subjects. No significant difference in superoxide dismutase activity between patients and healthy subjects was noticed. Decreased antioxidant system and increased malondialdehyde and homocysteine in Tunisian rheumatoid arthritis patients confirm the implication of the oxidative stress in rheumatoid arthritis and suggest the role of homocysteine as a pro-oxidant factor.

**INTRODUCTION:** Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis. This systemic autoimmune disease causes progressive joint destruction and loss of functional capacity. Although, the physiopathology of RA is still largely unknown, both genetic <sup>1</sup> and environmental factors were involved <sup>2</sup>.

Besides, the RA has not yet been recognized as an oxidative stress disease, despite the chronic oxidative stress observed in synovial T lymphocytes of RA patients due to the production of intracellular reactive oxygen species (ROS) <sup>3</sup>.

In fact, many studies have shown that the antioxidant system was impaired in patients <sup>4-5</sup> and oxidative stress markers were increased in patients with RA <sup>6, 7</sup>. To the best of our knowledge, this is the first study performed in Tunisian patients with RA and the largest RA study population actually analysed for oxidative stress parameter correlations.

<p><b>QUICK RESPONSE CODE</b></p>	<p><b>DOI:</b> 10.13040/IJPSR.0975-8232.7(6).2591-96</p> <hr/> <p>Article can be accessed online on: <a href="http://www.ijpsr.com">www.ijpsr.com</a></p> <hr/> <p>DOI link: <a href="http://dx.doi.org/10.13040/IJPSR.0975-8232.7(6).2591-96">http://dx.doi.org/10.13040/IJPSR.0975-8232.7(6).2591-96</a></p>
-----------------------------------	--

The aim of this prospective study was to assess the antioxidant status by measuring the superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR) and catalase (CAT) erythrocyte activities and the total antioxidant status (TAS) levels in patients with RA. Besides, we wanted to quantify the pro-oxidant parameters (MDA and Hcy) in RA affected patients compared to a control cohort.

## MATERIALS & METHODS:

### The study population:

172 patients, with no smoking history, were enrolled in this study (average age:  $48 \pm 13$  years), that men represent 2.9 % to eliminate gender differences in the results. The mean RA onset was  $3 \pm 2$  years before the beginning of this study. Patients were recruited from the Rheumatology Department of the University Hospital "Farhat Hached", Sousse-Tunisia. All the patients were diagnosed according to the American Rheumatism Association criteria, 1987 (ARA) <sup>8</sup>. View the rarity of a disease, the collection of subjects took around 18 months.

Patients suffering from chronic disorders such as thyroid dysfunction, liver or kidney disease, inflammatory disease, infection and those who are smoking, consuming alcohol or any antioxidant supplements at the start of the study or in the preceding month were excluded. 79.6% of patients (125 women and 4 men) have been treated by the Methotrexate for at least three months.

The control group consists of 147 unrelated healthy volunteers (70.1 % women, average age:  $46 \pm 7$  years).

### Blood samples processing:

Venous blood samples from RA patients and healthy volunteers were collected in heparinized and without anti-coagulant tubes. Informed consent was obtained from all patients and controls and the study was carried out according to the Tunisian guidelines for genetic research. The heparinized whole blood was used to determine the erythrocyte activities of GPx, GR, SOD and CAT, while plasma was used to evaluate TAS and MDA levels. Hcy levels were determined on serum.

Plasma levels glucose, a renal profile (urea, creatinine, uric acid) levels and serum levels of total cholesterol and triglycerides were measured with colorimetric assay using an automated system (Cx5 and Cx9 Pro Bechman Coulter-Fuller-Ton CA).

The GPx activity was determined using cumene hydroperoxide as an oxidant of glutathione. The oxidized glutathione is immediately converted to the reduced form with a concomitant oxidation of NADPH to NADP<sup>+</sup>.

The decrease in absorbance at 340 nm was measured (Ransel, Randox, Antrim, UK). The GR catalyses the reduction of glutathione in the presence of NADPH which is oxidized to NADP<sup>+</sup>. The decrease in absorbance at 340 nm was measured (GR, Randox, Antrim, UK). SOD activity in erythrocytes was measured by enzymatic colorimetric method at 505 nm: by the rate of inhibition of I.N.T. [(2-(4iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride) reduction (Ransod, Randox, Antrim, UK). GPx, GR and SOD activities were expressed in unit per gram of hemoglobin.

CAT activity was measured using the molybdate colorimetric method described by Góth et al. (1991) <sup>9</sup> and expressed in kilo unit per gram of hemoglobin.

TAS rates were assayed by colorimetric method at 600 nm (TAS, Randox, Antrim, UK) and expressed in milli mole per litre.

Plasma MDA was determined by the Yagi spectrofluorometric method <sup>10</sup> which is based on thiobarbituric acid (TBA) reaction at 95°C. The fluorescence was detected at 553 nm after excitation at 515 nm. The results were expressed as micro mole per litre ( $\mu\text{mol/l}$ ). Serum Hcy was measured by fluorescence polarization immunoassay (Abbott, AxSYM) expressed in micro mole per litre ( $\mu\text{mol/l}$ ). All bioassays were performed in Biochemistry laboratory, Farhat Hached hospital, Sousse, Tunisia.

**RESULTS:** Demographic, clinical and biologic data of study groups are shown in **Table 1**. Total cholesterol and triglyceride concentrations were significantly elevated in patients compared to controls unlike creatinine concentration was significantly increased among healthy subjects. Glucose, urea and uric acid variations showed no significant differences between groups.

**TABLE 1: DEMOGRAPHIC, CLINICAL AND BIOLOGICAL DATA OF PATIENTS AND CONTROLS**

Parameters	Patients (n=172)	Controls (n=147)	P
Women/Men (%)	97.1/2.9	70.1/29.9	0.000
Age (years)	48±13	46±7	0.089
BMI ( Kg/m <sup>2</sup> )	26.47±5.49	27.8±3.69	0.079
Menopausal women (%)	53.89	15.12	-
Duration of disease (years)	3.24 ±2.18	-	-
Anti-CCP antibodies (%)	64.9	-	-
Anti-Nuclear antibodies (%)	21.9	-	-
Rheumatoid factor positive (%)	59.3	-	-
DAS 28 score	5.03±2.41		
Glucose (mmol/l)	5.26±1.79	5.07 ±0.68	0.26
Urea (mmol/l)	4.80±1.68	4.84±1.46	0.86
Creatinine (µmol/l)	66.82±17.80	74.91±24	0.004
Uric acid (µmol/l)	210.45±91.28	207.55±90.45	0.79
Total cholesterol (mmol/l)	4.83±1.02	4.47±0.86	0.001
Triglyceride (mmol/l)	1.67±0.83	1.21±0.71	<0.001

Anti-CCP antibodies: antibodies against cyclic citrullinated peptide. DAS 28: disease activity score. mmol/l, milli moles per litre; µmol/l, micro mole per litre, P, significance (2-tailed)..

In our study, a significant decrease of CAT, GPx and GR activities as well as a lower TAS were noticed among patients compared to controls. Conversely, MDA and Hcy levels were significantly higher in patients than in healthy subjects. However, no difference of erythrocyte SOD activity between patients and controls was found. Those Variations were illustrated in **Table 2**.

**TABLE 2: THE DISTRIBUTION OF ANTI-OXIDANT AND OXIDANT PARAMETERS IN PATIENTS AND CONTROL SUBJECTS**

Populations Anti-oxidant/oxidant parameters	Patients (n=172)	Controls (n=147)	P	95 % confidence interval
CAT (x±σ kU/gHb)	240.93 ± 118	288.5 ±99.7	P < 10 <sup>-3</sup>	[- 73.671; - 21.522]
GPx (x±σ U/gHb)	133.45±47.25	153. 83 ±31.5	P=10 <sup>-3</sup>	[- 32.768; - 7.997]
GR (x±σ U/gHb)	8.06±3.2	8.95± 3.26	P= 0.032	[- 1.695; - 0.075]
SOD (x±σ U/gHb)	1740 ± 600	1718 ± 604	NS	[- 123.451; 167.455]
TAS (x±σ mmol/l)	1.68±0.29	1.75 ± 0.22	P=0.034	[- 0.135 ; - 0.005]
MDA (x±σ µmol/l)	1.533±0.849	0.658±0.350	P<10 <sup>-3</sup>	[0.704; 1.043]
Hcy (x±σ µmol/l)	13.74±7.03	10.46±3.64	P<10 <sup>-3</sup>	[1.922; 4.646]


Anti-oxidant parameters: TAS, total antioxidant status; GPx, glutathione peroxidase; GR, glutathione reductase; CAT, catalase; SOD, superoxide dismutase. Oxidant parameters: MDA, malondialdehyde; Hcy, homocysteine. kU/gHb, kilo unit per gram of hemoglobin; U/gHb, unit per gram of hemoglobin; mmol/l, milli moles per litre; µmol/l, micro mole per litre, P, significance (2-tailed).

Furthermore, relationship between the oxidative stress parameters establishment revealed statistically significant positive correlations between GPx and TAS (r=0.346; P=10<sup>-3</sup>) (**Fig.1**), and also between GR and SOD activities (r=0.246; P=0.003) (**Fig.2**). However, a negative correlation was demonstrated between Hcy and GPx (r=-0.305; P=0.005) in one hand and Hcy and GR (r=-0.208; P=0.012) in the other hand.

In the other side, significant negative correlation was found between age and SOD in patients (r=-0.213; P=0.008). Whereas, significant positive correlation was detected between age and Hcy in patients (r=0.250; P=10<sup>-3</sup>).

To fulfill patient's age impact scope by 10-year age range the HCY and SOD were important result as below:

Significant SOD-decrease in 8<sup>th</sup> range compared by 3<sup>rd</sup> range ( $1202 \pm 372$  U/gHb vs  $2400 \pm 890$  U/gHb;  $P=7.10^{-3}$ ), significant Hcy-increase ( $16.17 \pm 5$   $\mu\text{mol/l}$  vs  $12.71 \pm 6$ ;  $P=0.05$ ).




**FIG. 1: THE CORRELATION BETWEEN GPx ACTIVITY AND TAS LEVELS**

“It is a bottom line that represents the relationship between the values of the GPx activity and rates of SAT. Patients with high GPx activity have a relatively high TAS and screw to it.”

GPx, glutathione peroxidase; TAS, total antioxidant status; mmol/l, milli moles per litre; U/gHb, unit per gram of hemoglobin; RA, rheumatoid arthritis.

Circles indicate the observed values of GPx and TAS



**FIG. 2: THE CORRELATION BETWEEN SOD AND GR ACTIVITIES IN RA PATIENTS**

It is a bottom line that represents the relationship between the values of the GPx and SOD activities. Patients with high GR activity have a relatively high SOD activity and screw to it.”

GPx, glutathione peroxidase; SOD, superoxide dismutase; U/gHb, units per gram of hemoglobin; RA, rheumatoid arthritis.

Circles indicate the observed values of SOD and GR

**DISCUSSION:** In the first line of antioxidant defense, the SOD catalyzes the dismutation of the first product of ROS, the superoxide anion ( $\text{O}_2^-$ ) into  $\text{H}_2\text{O}_2$ <sup>11</sup>. Our data demonstrate that the activity of erythrocyte SOD is unchanged in patients with RA compared to healthy individuals which is in line with a previous study performed by Sarban et al.<sup>12</sup>. However, it is undeniable that further studies done on patients with RA have shown a decreased erythrocyte SOD activity in their patient’s cohort<sup>5, 13</sup>. This lack of results reproducibility from one study to another could be explained by the intervention of environmental factors in the onset of the disease between one population to another and also by the size of the study cohort which without any doubt could play an important role in the interpretation of the results. It is worthy to note that to our knowledge, our RA study population is the largest one actually reported.

Further studies performed on patients with RA have shown a strong association between the disease onset and an overproduction of ROS by synovial T lymphocytes<sup>3</sup> and neutrophils, which are the main actors in inflammation and destruction of joints<sup>14</sup>. Several cytokines were also implicated in the articulation damage and correlated with synovial ROS generation, mainly tumor necrosis factor alpha ( $\text{TNF}\alpha$ )<sup>15</sup>.

These factors activate the mitochondrial SOD ( $\text{SOD}_2$ )<sup>16</sup> and inhibit the cytosolic SOD ( $\text{SOD}_1$  or Copper/Zinc-SOD)<sup>11</sup> and the extracellular SOD ( $\text{SOD}_3$ )<sup>17</sup>. GPx and catalase then metabolize  $\text{H}_2\text{O}_2$ , which is produced by the SOD. The GPx acts also on lipid hydroperoxides resulting from the peroxidation of polyunsaturated fatty acids<sup>18</sup>.

In our study, GPx activity was significantly lower in patient’s erythrocytes compared to controls, which is in accordance with previous researches<sup>12, 13</sup>. Furthermore, catalase activity significantly decreased in RA patients which is in line with the study performed by Sarban et al.<sup>12</sup> and El-barbary et al.<sup>5</sup>. A similar decrease of CAT activity was also detected in the synovial fluid of RA patients as reported by seven et al.<sup>13</sup>.

In our study population, plasma TAS levels in patients with RA were significantly lower than in healthy individuals and confirm the study of Abdel-Rahman et al.<sup>19</sup> who evaluated the TAS only in female patients with RA.

We have also demonstrated that Lipid peroxidation reflected by MDA levels significantly increased in RA patients compared to normal healthy subjects; these results are in agreement with many studies in plasma<sup>6, 20</sup>, in erythrocytes<sup>4</sup> and in synovial fluid<sup>13, 15</sup>. As a whole, the negative correlation deduced between MDA and the activities of GPx and CAT<sup>13</sup> confirm the pro-oxidant effect of MDA in RA onset. Enhanced lipid peroxidation may occur as a result of imbalance between scavenging mechanisms and free radical generation process. In Rheumatoid arthritis, the ROS are produced in synovial infiltrates in inflamed joints and correlates with DAS\_28<sup>21</sup> and with synovial MDA<sup>15</sup>. These reactive species, if not scavenged, lead to lipid peroxidation. Synovial MDA was found to be correlated to disease activity score (DAS\_28), hence it can be used as marker of disease activity<sup>15</sup>.

In the present study, Hcy was significantly increased in RA patients, which is in agreement with a previous finding reported by Willers et al.<sup>22</sup>. This hyperhomocysteinemia could be explained by the administration of methotrexate and corticoid that are previously reported to generate such effect<sup>23</sup>. It is actually known that, homocysteine is an amino acid transformed in methionine by dependent-folate remethylation and methotrexate interferes with folate metabolism which explains the increase of homocysteine levels in methotrexate treated RA patients<sup>24</sup>.

In one hand, negative correlations between Hcy and antioxidant activities of GPx and GR demonstrated that Hcy has pro-oxidant role in RA: In fact, Matté et al.<sup>25</sup> showed that Hcy, administrated to mice, decrease enzymatic and non-enzymatic antioxidant defense and increase lipid peroxidation. In the other hand, positive correlation with age and negative correlation between SOD and age confirm that the antioxidant system impairs with aging and pro-oxidants grow up.

Some of our findings did not match the previously reported ones which could be attributed to the disease duration, the treatments administrated to RA patients and the study population size and characteristics (subject's number, age...) in addition to the environmental factors. In fact, such variability was also detected in a previous report due to treatment and disease period<sup>26</sup>.

**CONCLUSION:** In summary, our data demonstrate that the oxidative stress is implicated in the RA onset and is manifested by impaired antioxidant parameters and an increase of plasma MDA and Hcy. Thus, we think that the administration of some antioxidant enzymes to these patients may protect them from the ROS generation and decrease their serum Hcy levels. Thus RA patients will be protected from cardiovascular disease resulting from hyperhomocysteinemia.

**ACKNOWLEDGEMENTS:** The authors are grateful to the patients and volunteers for their collaboration, to Dr Elyes Bouajina and his team (Rheumatology Department, Farhat Hached hospital, Sousse, Tunisia) for collecting blood samples from RA patients and the staff of the Biochemistry Laboratory (Farhat Hached University Hospital, Sousse, Tunisia) for their precious technical support.

**CONFLICT OF INTEREST:** The authors declare that they have no competing interest.

## REFERENCES:

1. Kurkó J, Besenyei T, Laki J, Glant TT, Mikecz K and Szekanez Z: Genetics of rheumatoid arthritis - a comprehensive review. *Clinical Reviews in Allergy and Immunology* 2013; 45: 170-9.
2. Ruiz-Esquide V and Sanmartí R: Tobacco and other environmental risk factors in rheumatoid arthritis. *Reumatologica Clinica* 2012; 8: 342-50.
3. Remans PHJ, Van Oosterhout M, Smeets TJM, Sanders M, Frederiks WM and Reedquist KM, et al.: Intracellular free radical production in synovial T lymphocytes from patients with rheumatoid arthritis. *Arthritis & Rheumatism* 2005; 52: 2003-9.
4. Pasupathi P, Deepa M, Rani P and Sankar RR: Circulating lipid peroxidation, plasma and erythrocyte antioxidant status in patients with rheumatoid arthritis. *Bangladesh Medical Research Council Bulletin* 2009; 35: 57- 62.
5. El-barbary AM, Abdel Khalek MA, Elsalawy AM and Hazaa SM: Assessment of lipid peroxidation and antioxidant status in rheumatoid arthritis and osteoarthritis patients. *The Egyptian Rheumatologist* 2011; 33: 179-85.

6. Veselinovic M, Barudzic N, Vuletic M, Zivkovic V and Tomic-Lucic A: Oxidative stress in rheumatoid arthritis patients: relationship to diseases activity. *Molecular and cellular Biochemistry* 2014; 391: 225-32.
7. Nakajima A, Aoki Y, Shibata Y, Sonobe M, Terajima F, Takahashi H, Saito M, Taniguchi S, Yamada M and Nakagawa K: Identification of clinical parameters associated with serum oxidative stress in patients with rheumatoid arthritis. *Modern Rheumatology* 2014; 24: 926-30.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis & Rheumatology* 1988; 31: 315-24.
9. Góth L: A simple method for determination of serum catalase activity and revision of reference range. *Clinica Chimica Acta* 1991; 196: 143-52.
10. Yagi K: Simple assay for the level of total lipid peroxides in serum or plasma. *Methods in molecular biology, Free Radical and antioxidant Protocols* 1998; 108: 101-6.
11. Afonso V, Santos G, Collin P, Khatib AM, Mitrovic D and Lomri N: TNF- $\alpha$  down-regulates human Cu/Zn superoxide dismutase 1 promoter via JNK/AP-1 signaling pathway. *Free Radical Biology Medicine* 2006; 41: 709-21.
12. Sarban S, Kocyigit A, Yazar M and Isikan UE: Plasma total antioxidant capacity, lipid peroxidation and erythrocyte antioxidant enzyme activities in patients with rheumatoid arthritis and osteoarthritis. *Clinical Biochemistry* 2005; 38: 981-6.
13. Seven A, Güzel S, Aslan M and Hamuryudan V: Lipid, protein, DNA oxidation and antioxidant status in rheumatoid arthritis. *Clinical Biochemistry* 2008; 41: 538-43.
14. Kundu S, Bala A, Ghosh P, Mukhopadhyay D, Mitra A, Sarkar A, Bauri AK, Ghosh A, Chattopadhyay S and Chatterjee M: Attenuation of oxidative stress by allylpyrocatechol in synovial cellular infiltrate of patients with Rheumatoid Arthritis. *Free Radical Research* 2011; 45: 518-26.
15. Datta S, Kundu S, Ghosh P, De S, Ghosh A and Chatterjee M: Correlation of oxidant status with oxidative tissue damage in patients with rheumatoid arthritis. *Clinical Rheumatology* 2014; 33: 1557-64.
16. Kinningham KK, Xu Y, Daosukho C, Popova B and St Clair DK: Nuclear factor kappa B- dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2. *Biochemistry Journal* 2001; 353: 147-56.
17. Stralin P and Marklund SL: Multiple cytokines regulate the expression of extracellular superoxide dismutase in human vascular smooth muscle cells. *Atherosclerosis* 2000; 151: 433-41.
18. Halliwell B and Gutteridge JMC. *Free Radicals in Biology and Medicine*. In: Halliwell, B, Gutteridge, JMC, editors. Oxford University Press. Oxford: UK; 1999.
19. Abdel-Rahman M, Elebiary AS, Hafez SS, Mohammed HE and Abdel Moneim AE: Therapeutic activity of bee-stings therapy in rheumatoid arthritis causes inflammation and oxidative stress in female patients. *International Journal of Research in Ayurveda and Pharmacy* 2013; 4: 316-21.
20. Patil AB, Patil A, Shah S and Patil M: Antioxidant gap and lipid peroxidation in patients with rheumatoid arthritis: relationship to disease manifestations and activity. *Asian Pacific Journal of Tropical Disease* 2012; S592-5.
21. Kundu S, Ghosh P, Datta S, Ghosh A, Chattopadhyay S and Chatterjee M: Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis. *Free Radical Research* 2012; 46: 1482-9.
22. Willers J and Hahn A: Cardiovascular risk in patients with rheumatoid arthritis: assessment of several traditional risk parameters and a German risk score model. *Rheumatology International* 2012; 32: 3741-9.
23. Shea B, Swinden MV, Ghogomu ET, Orti Z, Katchamart W, Rader T, et al: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *Journal of Rheumatology* 2014; 41: 1049-60.
24. Mahadeo KM, Dhall G, Panigrahy A, Lastra C and Ettinger LJ: Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. *Pediatric Hematology Oncology* 2010; 27:46-52.
25. Matté C, Stefanello FM, Mackedanz V, Pederzoli CD, Lamers ML, Dutra-Filho CS, et al: Homocysteine induces oxidative stress, inflammatory infiltration, fibrosis and reduces glycogen/glycoprotein content in liver of rats. *International Journal of Developmental Neuroscience* 2009; 27: 337-44.
26. Neigrei C, Balanescu A, Ilie M, Margina D, Berghea F and Nicolescu F: Oxidative stress markers and the disease score in rheumatoid arthritis [Abstract]. *Toxicology Letters* 2012; 211: S43-216.

**How to cite this article:**

Ben-Hadj Mohamed M, Khelil S, Dbibis MB, Khelifi L, Chahed H, Ferchichi S, Bouajina E and Miled A: A Case Control Study of Antioxidant and Oxidant Status in Tunisian Rheumatoid Arthritis Patients . *Int J Pharm Sci Res* 2016; 7(6): 2591-96.doi: 10.13040/IJPSR.0975-8232.7(6).2591-96.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)